• Earlier in June 2026, Travere Therapeutics reported long-term Phase 3 DUPLEX open-label extension data showing durable proteinuria reductions and up to five years of tolerability for FILSPARI in focal segmental glomerulosclerosis, alongside its first non-GAAP profitable quarter driven by the drug’s commercial performance.
• This combination of sustained clinical benefit in a rare kidney disease and an early move into profitability highlights how central FILSPARI has become to Travere’s therapeutic and financial profile.
• We’ll now examine how FILSPARI’s durable FSGS data and Travere’s first non-GAAP profitable quarter reshape the company’s investment narrative.

Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Travere Therapeutics Investment Narrative Recap

To own Travere today, you need to believe FILSPARI can anchor a durable rare kidney franchise while the company broadens its revenue base beyond a single flagship drug. The DUPLEX open label data reinforces the FSGS label clinically, but the near term story still hinges on execution in IgAN and FSGS launches, and on how quickly Travere can manage FILSPARI’s REMS and safety profile without derailing access or uptake.

Against that backdrop, Travere’s first non GAAP profitable quarter, driven largely by FILSPARI, may matter as much as the new DUPLEX data. It suggests the commercial engine around FILSPARI is gaining operating leverage just as the drug’s clinical and regulatory footing in FSGS and IgAN strengthens, which could influence how investors weigh upcoming regulatory decisions and any future changes to monitoring requirements.

Yet, in contrast, investors should be aware that FILSPARI’s REMS tied to liver toxicity and pregnancy risk could still...

Travere Therapeutics’ narrative projects $1.2 billion revenue and $378.4 million earnings by 2029.

Uncover how Travere Therapeutics' forecasts yield a $53.57 fair value, a 3% upside to its current price.

Exploring Other Perspectives

Compared with the baseline view, the most optimistic analysts were already assuming revenue could reach about US$1.6 billion and earnings US$709.0 million by 2029, so this new FSGS durability data may either reinforce that bullish “near monopoly” FSGS thesis or prompt some to rethink how concentrated Travere’s risk really is.

Explore 6 other fair value estimates on Travere Therapeutics - why the stock might be worth as much as 64% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Travere Therapeutics research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Travere Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Travere Therapeutics' overall financial health at a glance.

Want Some Alternatives?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.